RHY
Rhythm Biosciences Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
11
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-12-07. The firm is engaged in the development and commercialization of Australian medical diagnostics technology for sale in domestic and international markets. The Company’s ColoSTAT a blood-base cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or unwilling to use available screening modalities. ColoSTAT is indicated to screen adults, aged 40 to 85, at average risk for developing Colorectal Cancer (CRC). The test-kit measures five specific biomarkers in the blood that either increase or decrease in quantity when CRC tumors are present.
📈 Performance
Price History
+105.55%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.41
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in RHY
11
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in RHY
704 days
RHY investor breakdown
💵 Income of investors
More than 200k
7%
150k - 200k
21%
100k - 150k
29%
50k - 100k
29%
Less than 50k
14%
👶 Age of investors
18 - 25
26 - 34
18%
35 - 90
82%
🙋 Legal gender of investors
Female
45%
Male
55%
Pearlers who invest in RHY also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
📊 Share price
$90.18 AUD
NULL AUSTRALIA
NULL BETA
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
📊 Share price
$34.01 AUD
NULL US
NULL EX AUSTRALIA
NULL BETA
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
📊 Share price
$57.36 AUD
NULL GLOBAL
NULL SMART BETA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
📊 Share price
$104.08 AUD
NULL GLOBAL
NULL EX AUSTRALIA
NULL BETA
Pilbara Minerals Ltd. engages in the exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 446 full-time employees. The company went IPO on 2007-09-19. The firm is primarily engaged in the exploration, development, and mining of minerals in Australia. Its 100% owned Pilgangoora hard-rock lithium operation is located approximately 120 kilometers (kms) from Port Hedland in Western Australia’s resource-rich Pilbara region. The operation consists of two processing plants: the Pilgan Plant, located on the northern side of the Pilgangoora area and produces spodumene and tantalite concentrates, and the Ngungaju Plant is located to the south produces spodumene concentrate. The company owns 70% of the Mt Francisco project, which is located 50 km south-west of the Pilgangoora Project and hosts the large occurrence of outcropping pegmatites located nearby to Port Hedland. The company is also pursuing a proposed downstream joint venture (JV) for the development of an approximately 43,000 tons per annum lithium carbonate equivalent (LCE) lithium chemical conversion facility in South Korea.
📊 Share price
$4.67 AUD
NULL RESOURCES
Want more shares? Try these...
Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. The firm specializes in the development and delivery of non-invasive medical imaging software and services. The firm is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The firm's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The firm also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.
📊 Share price